The prevalence of significant HIV-associated co-infections and clinical data of HIV/AIDS outpatients in the context of dolutegravir (DTG) transition are sparsely reported in Vietnam. Treatments of HIV co-infection, including antifungals, anti-tuberculous drugs, and direct-acting antiviral agents for viral hepatitis C, potentially challenge the efficacy of DTG-based therapies in terms of drug-to-drug interactions. We conducted a single-center, cross-sectional study between June and October 2020 in Ho Chi Minh City, Vietnam. HIV-infected outpatients were enrolled in the study when they attended the clinic to receive medical consultations and antiretroviral therapy (ART). Descriptive analyses were performed to describe the data. A total of 406 HIV-infected participants were enrolled in the study. The prevalence of HIV co-infected with chronic viral hepatitis B and C were 9.9% and 10.6%, respectively. Approximately 22.2% of HIV-infected patients had a history of tuberculosis treatment, and roughly 9% of participants experienced invasive fungal infections, mainly cryptococcosis, taralomycosis, and Pneumocystic jirovecii pneumonia. History of sexually transmitted diseases accounted for 40.4%. At the time of DTG transition, roughly 93% of patients were clinically stable, with a median CD4 count of 603 cells/µl. Two-thirds of HIV-infected patients achieved viral suppression (HIV viral load threshold < 20 copies/ml). A total of thirteen (3.2%) patients were ongoingly undertaking protease-inhibitors-based second-line ART regimens. The ART adherence was assessed at 92.1%. The prevalence of HIV-associated co-infections is still high in the context of DTG transition in Vietnam. More effort is needed in order to achieve the UNAIDS 90-90-90 targets.
 Global HIV and AIDS statistics | Avert 2020. [Internet].
Available from: https://www.avert.org/global-hiv-and-aids-statistics. [(Accessed and cited on 12 March 2021].
 World Health Organization. Transition to new antiretroviral
drugs in HIV programmes: clinical and programmatic considerations. Geneva: 2017.
[Internet]. [Accessed and cited on 20 June 2021]. Available from: http://apps.who.int/iris/bitstream/10665/255887/1/WHO-HIV-2017.23-eng.pdf?ua=1.
 WHO report
2018 on Dolutegravir program [Internet]. [(Accessed and cited 20 on June 2021].
Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/number-of-new-hiv-infections.
J, Lessells R, Drain PK, Naidoo K, de Oliveira T, Pillay Y, et al. Dolutegravir
for first-line antiretroviral therapy in low-income and middle-income countries:
uncertainties and opportunities for implementation and research. Lancet HIV. 2018;
New high-quality antiretroviral therapy to be launched in South Africa, Kenya, and
over 90 low- and middle-income countries at a reduced price, 2017 [Internet]. [Accessed
and cited on 20 June 2021]. Available from: http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2017/september/20170921_TLD.
 Ho Chi
Minh City, Vietnam Metro Area Population 2021. [Internet]. [Accessed and cited on
20 June 2021]. Available from: https://www.macrotrends.net/cities/22458/ho-chi-minh-city/population.
Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection:
Recommendations for a Public Health Approach. 2nd edition. Geneva: World Health
Organization; 2016. ANNEX 10, WHO clinical staging of HIV disease in adults, adolescents,
and children. [Internet]. [Accessed and cited on 20 June 2021]. Available from:
ambitious treatment target to help end the AIDS epidemic | UNAIDS [Internet]. (Accessed
and cited on 15 July 2021). Available from http://www.unaids.org/en/resources/documents/2014/90-90-90.
 Mitku AA,
Dessie ZG, Muluneh EK, Workie DL. Prevalence and associated factors of TB/HIV co-infection
among HIV Infected patients in Amhara region, Ethiopia. Afr Health Sci. 2016; 16:588-95.
 Le T, Wolbers
M, Chi NH, Quang VM, Chinh NT, Lan NP, et al. Epidemiology, seasonality, and predictors
of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City,
Viet Nam. Clin Infect Dis. 2011; 52:945-52.
R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of
disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect
Dis. 2017; 17:873-881.
 Cohen MS,
Council OD, Chen JS. Sexually transmitted infections and HIV in the era of antiretroviral
treatment and prevention: the biologic basis for epidemiologic synergy. J Int
AIDS Soc. 2019; 22 Suppl 6: e25355.
V, Ramachandran VG, Mogha NS, Bharadwaj M. Hepatitis B & C virus infection in
HIV seropositive individuals & their association with risk factors: A hospital-based
study. Indian J Med Res. 2018; 147:588-593.
D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B,
and HIV: prevalence, AIDS progression, response to highly active antiretroviral
therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005; 19:593-601.
G, Khamadi S, Okoth V, Madise N, Ezeh A, Ziraba A, et al. Hepatitis B, Hepatitis
C and HIV-1 Coinfection in Two Informal Urban Settlements in Nairobi, Kenya.
Plos One. 2015; 10: e0129247.
A, Matiko E, Khalid F, Welty S, Ali A, Othman A, et al. HIV and hepatitis B and
C co-infection among people who inject drugs in Zanzibar. BMC Public Health.
2017 ;17: 917.
ID, Uchechukwu C, Nto-Ezimah U. Prevalence of hepatitis B and C virus co-infection
in HIV positive patients attending a health institution in southeast Nigeria. Afr
Health Sci. 2020; 20:579-586.
JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis
C virus infection on HIV-1 disease progression and response to highly active antiretroviral
therapy. J Infect Dis. 2005;192: 992-1002.
 Kumar R,
Singla V, Kacharya Sk. Impact and management of hepatitis B and hepatitis C virus
co-infection in HIV patients. Trop Gastroenterol. 2008; 29:136-47.
MA, Alene M, Ketema DB, Mulatu S. Treatment failure and associated factors among
first-line patients on highly active antiretroviral therapy in Ethiopia: a systematic
review and meta-analysis. Glob Health Res Policy. 2019; 4:32.
 Hunt GM,
Dokubo EK, Takuva S, de Oliveira T, Ledwaba J, Dube N, et al. Rates of virological
suppression and drug resistance in adult HIV-1-positive patients attending primary
healthcare facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother.
2017; 72: 3141-3148.
TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, et al. Accumulation of
HIV-1 drug resistance after continued virological failure on first-line ART in adults
and children in sub-Saharan Africa. J Antimicrob Chemother. 2016; 71:2918-27.
F, Esber A, Musingye E, Reed D, Crowell TA, Cham F, et al. HIV virologic failure
and its predictors among HIV-infected adults on antiretroviral therapy in the African
Cohort Study. Plos one. 2019; 14: e0211344.
 Barth RE,
van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of
adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic
review. Lancet Infect Dis. 2010; 10:155-66.
 Bain LE,
Nkoke C, Noubiap JJN. UNAIDS 90-90-90 targets to end the AIDS epidemic by 2020 are
not realistic: comment on “Can the UNAIDS 90-90-90 target be achieved? A systematic
analysis of national HIV treatment cascades”. BMJ Glob Health. 2017; 2:
KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. International
Study of Patients with HIV on Rifampicin ING study group. Dolutegravir-based Antiretroviral
Therapy for Patients Coinfected with Tuberculosis and Human Immunodeficiency Virus:
A Multicenter, Noncomparative, Open-label, Randomized Trial. Clin Infect Dis. 2020;
RK, Patel M, Paturi DK, Pal D, Mitra AK. Clinically relevant drug-drug interactions
between antiretrovirals and antifungals. Expert Opin Drug Metab Toxicol. 2014; 10:561-80.
(Dolutegravir) Package Insert. Research Triangle Park, NC: GlaxoSmithKline; 2013.